Skip to main content
OpenTrials
Completed

NCT Number: NCT07168902

Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension

Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults with Primary Open Angle Glaucoma or Ocular Hypertension

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Glaucoma Eye Diseases Ocular Hypertension

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Global Research Management, Inc., Glendale, California, United States

Loading trial locations.

About this study

This study will evaluate the safety and efficacy of BL1107 in adults with primary open-angle glaucoma or ocular hypertension in both eyes. This is a randomized, double-masked, parallel comparison to evaluate two concentrations of BL1107 in both eyes compared with timolol 0.5% for 28 days.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Ocular hypertension or primary open-angle glaucoma in each eye

Exclusion criteria

  • History of orthostatic hypotension
  • Any active ocular disease
  • Anticipated wearing of contact lenses during study
  • Contraindication to pupil dilation

Treatment and study plan

BL1107 Low dose

Drug

Dosed twice daily for 28 days.

BL1107 High dose

Drug

Dosed twice daily for 28 days.

timolol maleate 0.5%

Drug

Dosed twice daily for 28 days.

Primary outcomes

  1. Change from baseline in visual field mean deviation in the study eye at Day 28/Exit.

    Time frame: Assessed at Day 28

Secondary outcomes

  1. Proportion of participants achieving ≥15-letter improvement in low-luminance best-corrected visual acuity (LL-BCVA) in the study eye at Day 28/Exit.

    Time frame: Assessed at Day 28

  2. Proportion of participants achieving ≥10-letter improvement in low-luminance best-corrected visual acuity (LL-BCVA) in the study eye at Day 28/Exit.

    Time frame: Assessed at Day 28

  3. Hour-matched change from Baseline in intraocular pressure (IOP) in the study eye at Day 28/Exit.

    Time frame: Assessed at Day 28

Sponsors and collaborators

Lead sponsor

Bausch & Lomb Incorporated

Industry

Registry information

Official study title

A Phase 2 Evaluation of the Safety, Ocular Tolerability, and Efficacy of Topical Ophthalmic BL1107 Versus Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Sep 11, 2025
Registry last updated
Jul 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.